MyMedR

Displaying all 4 publications

Abstract:

Sort:

The association between fear of missing out and mobile phone addiction: a meta-analysis

Zhang Y, Shang S, Tian L, Zhu L, Zhang W

BMC Psychol, 2023 Oct 17;11(1):338.
PMID: 37848985 DOI: 10.1186/s40359-023-01376-z

BACKGROUND: Numerous studies have explored the association between fear of missing out and mobile phone addiction, but there are different viewpoints and the results are inconsistent. This study intends to estimate the strength of the correlation between fear of missing out and mobile phone addiction in general through a meta-analysis, and to analyze the influencing factors of the inconsistent results of previous studies.
METHODS: We Searched China National Knowledge Infrastructure Database, Wan fang Database, CQVIP Journal Database、Web of Science Core Collection, Elsevier SD, Springer Online Journals, Medline, EBSCO-ERIC, SAGE Online Journals, PsycINFO, PsycArticles and ProQuest Dissertations and Theses。85 studies (90 independent effect size) were included from 2016 to 2023。The pooled correlation coefficient of the association between fear of missing out and mobile phone addiction was calculated by a random effects model using Comprehensive Meta-Analysis(Version 3.3).
RESULTS: The main effect analysis revealed a high positive correlation between fear of missing out and mobile phone addiction (r = 0.47, 95%CI [0.44, 0.50]). Furthermore, the measurements of mobile phone addiction moderated the strength of the association between fear of missing out and mobile phone addiction, with the highest correlation measured using MPATS and the lowest correlation measured using MPDQ. The age, gender, year of publication, cultural background, and the measurements of fear of missing out had no significant effect on the correlation between fear of missing out and mobile phone addiction.
CONCLUSION: The results indicated that fear of missing out was closely related to mobile phone addiction, which complied with the I-PACE model. Psychological services and mental health services should be developed to reduce the emergence of fear of missing out in the digital age and thus alleviate dependence on devices.
Fulltext Survey of mosquito species and mosquito-borne viruses in residential areas along the Sino-Vietnam border in Yunnan Province in China

Tian F, He J, Shang S, Chen Z, Tang Y, Lu M, et al.

Front Microbiol, 2023;14:1105786.
PMID: 36910188 DOI: 10.3389/fmicb.2023.1105786

Mosquitoes are capable of carrying complex pathogens, and their feeding habits on the mammalian blood can easily mediate the spread of viruses. Surveillance of mosquito-based arbovirus enables the early prevention and control of mosquito-borne arboviral diseases. The climate and geography of Yunnan Province in China are ideal for mosquitoes. Yunnan shares borders with several other countries; therefore, there exists a high risk of international transmission of mosquito-mediated infectious diseases. Previous studies have focused more on the Sino-Laos and Sino-Myanmar borders. Therefore, we focused on the neighborhoods of Malipo and Funing counties in Wenshan Prefecture, Yunnan Province, China, which are located along the Sino-Vietnam border, to investigate the species of mosquitoes and mosquito-borne viruses in the residential areas of this region. This study collected 10,800 mosquitoes from 29 species of 8 genera and grouped to isolate mosquito-borne viruses. In total, 62 isolates were isolated and classified into 11 viral categories. We demonstrated a new distribution of mosquito-borne viruses among mosquitoes in border areas, including Tembusu and Getah viruses, which can cause animal outbreaks. In addition, Dak Nong and Sarawak viruses originating from Vietnam and Malaysia, respectively, were identified for the first time in China, highlighting the complexity of mosquito-borne viruses in the Sino-Vietnam border region. The awareness of the importance of viral surveillance and prevention measures in border areas should be further encouraged to prevent future outbreaks of potentially infectious diseases.
Fulltext Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)

Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, et al.

Diabetes Metab Res Rev, 2014 Nov;30(8):726-35.
PMID: 24639432 DOI: 10.1002/dmrr.2541

BACKGROUND: This study assessed the efficacy and safety of the once-daily glucagon-like peptide-1 receptor agonist, lixisenatide, in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin ± sulfonylurea.
METHODS: In this 24-week, double-blind, placebo-controlled, multinational study, patients were randomized to lixisenatide 20 µg once daily or placebo. The primary endpoint was absolute change in glycated haemoglobin (HbA1c ) from baseline to week 24.
RESULTS: A total of 391 patients were randomized. Lixisenatide significantly reduced HbA1c levels compared with placebo (LS mean difference: -0.36%, p = 0.0004). A significantly higher proportion of lixisenatide-treated patients achieved HbA1c targets of <7% (p = 0.003) and ≤6.5% (p = 0.001) versus placebo. Lixisenatide was associated with a statistically significant reduction in 2-h postprandial plasma glucose after a standardized breakfast versus placebo (LS mean difference: -4.28 mmol/L, p
Fulltext Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, et al.

Mult Scler Relat Disord, 2021 May;50:102849.
PMID: 33676197 DOI: 10.1016/j.msard.2021.102849

Background Eculizumab, a terminal complement inhibitor, significantly reduced the risk of relapse compared with placebo in patients with anti-aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the PREVENT trial. We report efficacy and safety analyses in Asian patients in PREVENT and its open-label extension (OLE). Methods PREVENT was a double-blind, randomized, phase 3 trial. Patients with AQP4+ NMOSD were randomly assigned (2:1) to receive intravenous eculizumab (maintenance dose, 1200 mg/2 weeks) or placebo. Patients who completed PREVENT could receive eculizumab in an OLE. Analyses were performed in a prespecified subgroup of Asian patients. Results Of 143 patients enrolled, 52 (36.4%) were included in the Asian subgroup (eculizumab, n = 37; placebo, n = 15); 45 Asian patients received eculizumab in the OLE. Most Asian patients (86.5%) received concomitant immunosuppressive therapy. During PREVENT, one adjudicated relapse occurred in patients receiving eculizumab and six occurred in patients receiving placebo in the Asian subgroup (hazard ratio, 0.05; 95% confidence interval: 0.01-0.35; p = 0.0002). An estimated 95.2% of Asian patients remained relapse-free after 144 weeks of eculizumab treatment. Upper respiratory tract infections, headache, and nasopharyngitis were the most common adverse events with eculizumab in the Asian subgroup. Conclusion Eculizumab reduces the risk of relapse in Asian patients with AQP4+ NMOSD, with a benefit-risk profile similar to the overall PREVENT population. The benefits of eculizumab were maintained during long-term therapy. Clinical trial registration ClinicalTrials.gov identifiers: NCT01892345 (PREVENT); NCT02003144 (open-label extension).